Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial-Reference-Cited by-同舟云学术

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Published:2015-10 Issue:10 Volume:15 Page:1145-1155
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Margolis David A,Brinson Cynthia C,Smith Graham H R,de Vente Jerome,Hagins Debbie P,Eron Joseph J,Griffith Sandy K,Clair Marty H St,Stevens Marita C,Williams Peter E,Ford Susan L,Stancil Britt S,Bomar Melinda M,Hudson Krischan J,Smith Kimberly Y,Spreen William R

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference24 articles.

1. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks follow-up;Lee;PLoS One,2014

2. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials;Eron;Lancet Infect Dis,2013

3. A randomized phase 3 study comparing once-daily elvitegravir to twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results;Elion;J Acquir Immune Defic Syndr,2013

4. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial;Zolopa;J Infect Dis,2010

5. Quad's in it for antiretroviral therapy?;Schrijvers;Lancet,2012

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV;HIV RES CLIN PRACT;2024

2. Pittsburgh Sleep Quality Index (PSQI) Changes in Virologically Suppressed People Living with HIVSwitching to Long-Acting Cabotegravir and Rilpivirine;Biomedicines;2024-09-02

3. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV;AIDS;2024-07-02

4. Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa;British Journal of Clinical Pharmacology;2024-06-25

5. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine;AIDS;2024-05-30